Physician profile
Jorge Serna
NPI 1861486532
$8,882.42
in general payments reported to CMS, 2019-2025
36 companies · $1,499 in 2025
The $1,499 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $838 · 2020: $1,275 · 2021: $1,610 · 2022: $1,124 · 2023: $1,363 · 2024: $1,173 · 2025: $1,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,875 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,874.77 |
| Education | $160.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,158.52 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $1,339.27 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $814.86 | 2019-2025 | Krystexxa, Tavneos |
| Vifor Pharma, INC. | $520.47 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $448.13 | 2021-2025 | |
| Travere Therapeutics, INC. | $419.83 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $378.12 | 2023-2025 | Tarpeyo |
| Ardelyx, INC. | $345.72 | 2024-2025 | Ibsrela |
| Opko Pharmaceuticals, LLC | $281.26 | 2020-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $255.46 | 2021-2025 | Benlysta |
| Akebia Therapeutics INC | $230.71 | 2019-2022 | |
| Pfizer INC. | $181.56 | 2019-2023 | |
| Scpharmaceuticals INC. | $170.49 | 2025 | |
| Aurinia Pharma U.S., INC. | $168.33 | 2022-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.70 | 2023-2025 | Jardiance |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Serna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.